Regulatory

It is worth keeping patients, clinicians, pharmacists and the wider public front of mind when evaluating priorities and best next steps towards Identification of Medicinal Products(IMDP) and other emerging standards, writes Frits Stulp.

Every big shift will stir up dissenters, but these negative forces can actually offer a useful contribution if their concerns are fed into a continuous change program. This could make all the difference in regulatory information management transformation, writes Steve Gens.

In a sit-down with editors from our group publications, former FDA Commissioner Scott Gottlieb chatted with Pharm Exec on several topics, including the evolution of pricing and reimbursement for novel therapies-and the access fixes needed for future.

Ben Jacoby assesses the scope for disruption of the significant changes in medical device transparency and traceability requirements, and advises on a practical response.

Advice for developers in steering gene therapies from concept to trials to hopeful approval in what is an uniquely complex path.

HHS, FDA back Trump back cheaper foreign drugs to cut pharma costs. Jill Wechsler reports.

Agency focused on advancing testing and production methods, seeking input from other regions on common approaches.

In their latest article summarizing efforts to put each of the “American Patients First” blueprint's four strategies into action, Rick Kelly and Nisha Desai focus on the Lowering Out of Pocket (OOP) Costs strategy.

How R&D organizations can leverage FDA’s final guidance on pre-approval information exchange (PIE) to engage with payers prior to approval and launch.

What to make of the simmering public and political angst

New guidances open the door to interchangeables and less costly insulin.

In the third in a series of articles summarizing efforts to put each of the “American Patients First” blueprint's four strategies into action, Rick Kelly and Nisha Desai focus on “Incentivizing Lower List Prices.”

R&D organizations can leverage FDA’s final guidance on pre-approval information exchange, otherwise known as PIE, to engage with payers prior to regulatory approval and commercial launch.

A provision in a Senate health reform bill has reignited debate over the whether biological products should have to meet product quality standards established by the U.S. Pharmacopeia.

Congress is weighing in on drug pricing with a range of measures that differ in style and substance.

Cell and gene therapies in crosshairs of pricing focus, prompting stepped-up proposals on ways to finance these products.

Sabina Heinz and Elizabeth Baynton look at how the continued absence of approved products affecting the management of NASH patients.

In the first in a series of articles addressing each of the American Patients First blueprint 's four strategies, Rick Kelly and Nisha Desai focus on “Increasing Competition”.

Jill Wechsler looks at the proposed new FDA rules to beef up regulatory resources and promote digital technologies to support the development and marketing of safe and innovative over-the-counter therapies.

FDA is examining and updating its programs for overseeing global operations and international affairs.

New leadership faces a host of complex initiatives to promote innovation and protect public health.

Elvis Paćelat outlines some lessons from big pharma as medical device manufacturers succumb to new reporting obligations.

New FDA leader Ned Sharpless will seek further solutions to the opioid crisis and work to reduce cigarette use in adults and kids.

A new CDER “knowledge management” approach will see companies submit applications that can be transmitted to experts from multiple disciplines able to assess applications for new drugs and biologics in a timely and efficient manner.

Follow-on product naming, messaging challenge FDA, industry.